{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"0"}]}],"title":"QTcF Criteria: 450-<480"},{"categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"0"}]}],"title":"QTcB Criteria: 450-<480"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}]}],"title":"QTcB Criteria: 480-<500"}],"denoms":[{"counts":[{"groupId":"OG000","value":"217"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"ECG parameters included corrected QT interval using Bazett's formula (QTcB) and corrected QT interval using Fridericia's formula (QTcF). ECG criteria for abnormality: absolute value 450 - \\<480 msec, 480 - \\<500 msec, \\>=500msec. The number of participants with potentially clinically significant ECG findings at any visit were reported.","groups":[{"description":"Participants received 45 mg of dacomitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first.","id":"OG000","title":"Dacomitinib"},{"description":"Participants received 250 mg of gefitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first.","id":"OG001","title":"Gefitinib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety analysis set included all participants who received at least 1 dose of study medication, with treatment assignments designated according to actual study treatment received. Here, \"N\" (number of participants analyzed) signifies participants who were evaluable for this specified outcome measure.","reportingStatus":"POSTED","timeFrame":"From randomization until death or last date known as alive, up to 61 months","title":"Number of Participants With Clinically Significant Abnormality in Electrocardiogram (ECG)","type":"SECONDARY","unitOfMeasure":"Participants"}